Table 1.
Patient and disease characteristics
| Total (N = 59) | |
|---|---|
| Median age, y | 72 (54-81) |
| Female | 11 (19%) |
| Male | 48 (81%) |
| ECOG performance status score 0-1 | 56 (95%) |
| MCL International Prognostic Index | |
| Low risk | 8 (14%) |
| Intermediate risk | 28 (48%) |
| High risk | 21 (36%) |
| Missing data | 2 (3%) |
| Stage IV | 42 (71%) |
| Median number of previous lines of therapy | 2 (1-7) |
| Previous ASCT | 35 (59%) |
| Previous ibrutinib | 15 (25%) |
| S-IgG < 4 g/L | 11 (19%) |
| CD4 count < 200/mL | 16 (27%) |
| Histology | |
| Classical | 25 (42%) |
| Blastoid | 12 (20%) |
| Pleomorphic | 1 (2%) |
| Unknown | 21 (36%) |
| Ki67 | |
| ≤30% | 40 (68%) |
| >30% | 19 (32%) |
| TP53 mutational status at relapse | |
| Mutated | 18 (30%) |
| Unmutated | 28 (48%) |
| Not evaluable | 13 (22%) |
Data are number (percentage) or median (range).
ECOG, Eastern Cooperative Oncology Group; S-IgG, XXX.